« Back
Home /
Dalotuzumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）

Dalotuzumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）

Item no.	DCC-A209-100mg
Manufacturer	DCChemicals
CASRN	1005389-60-5
Amount	100 mg
Applications	other, IV
Specific against	other
Available
Manufacturer - Applications	Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Delivery expected until 6/19/2025

Express Delivery: Save 2 days

Compare

Add to wishlist

Recommend by mail